Target intelligence / Profile preview

null

Target
null
Molecular classification
Heat shock protein 70 (Hsp70): Molecular chaperone, Heat shock protein 90 (Hsp90): Molecular chaperone, Calreticulin: Endoplasmic reticulum chaperone, Nucleolin: Nucleolar phosphoprotein, S100A8: Calcium-binding protein, High mobility group box 1 (HMGB1): Non-histone chromatin-binding protein
01

Overview

This entry refers to multiple distinct proteins frequently associated with cellular stress responses, immunogenic cell death signals, and tumor immunity regulation, including heat shock proteins 70/90, calreticulin, nucleolin, S100A8, and HMGB1. Each plays unique roles in cancer biology—such as promoting tumor survival under stress conditions or acting as DAMPs that stimulate anti-tumor immunity—but they do not form a single molecular complex nor share an identical therapeutic targeting strategy. The grouping is commonly used when discussing immunogenic features of dying cells but should be split into individual targets for structured data extraction purposes[1][5].

Other names
HSP70HSP90calreticulin (CRT)nucleolinS100A8HMGB1
02

Mechanism of action

Drugs typically act by inhibiting the chaperone activity of heat shock proteins or modulating their release/function as damage-associated molecular patterns (DAMPs), thereby affecting tumor cell survival or immune activation[1].

03

Biological functions

Protein folding and stress response (Hsp70/Hsp90)Regulation of immune responses and apoptosis signalingPro-phagocytic signaling for immune clearance (calreticulin)Chromatin remodeling and inflammation mediation (HMGB1)
04

Disease associations

Cancer progression and recurrenceInflammationImmune modulation
05

Safety considerations

Targeting these molecules can affect normal cellular stress responses; inhibition may lead to toxicity due to impaired proteostasis or unintended immune activation.
06

Interacting drugs

Hsp70 inhibitors

1 more in the full profile.

07

Biomarkers

Tumor cell stress/death responsesImmunogenic cell deathPrognosis in cancer therapy

Beyond the preview

Go deeper on null.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on null.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call